MPP’s licences 2010 - 2022

For the past 12 years, MPP has applied its voluntary licensing and patent pooling model to secure more affordable access in low- and middle-income countries for life-saving medicines and health technologies.

In 2022, we signed four voluntary licensing agreements for the following products:

**cabotegravir (CAB)** LA for HIV PrEP with ViiV Healthcare;

An extended-release depot of ivermectin as a community level malaria vector control tool, using Medincell’s BEPO® LA platform;

**nilotinib** for the treatment of myeloid leukaemia with Novartis;

**ensitrelvir fumaric acid** an oral antiviral to combat COVID-19, with Shionogi.